Dexcom G7 lowers A1C in trial of Type 2 diabetes patients not using insulin

(AWP Alliance News) - DexCom announced publication of its CONNECT randomized controlled trial in The New England Journal of Medicine, showing its G7 continuous glucose monitor improved glucose control in adults with Type 2 diabetes not using insulin. G7 users had greater reductions in average blood sugar than those receiving routine care.

Benefits extended to participants taking GLP-1 therapies, supporting consideration of continuous glucose monitoring earlier in diabetes treatment. The results were first presented at the American Diabetes Association's 2026 Scientific Sessions.

https://www.businesswire.com/news/home/20261014236618/en/

Disclaimer: This news brief was created using generative artificial intelligence. DexCom Inc. published the original content used to generate this news brief via Business Wire on October 14, 2026, and is solely responsible for the information contained therein.